Medicine on the fringe: Stem cell-based interventions in advance of evidence

Stem Cells

Volumn 27, Issue 9, 2009, Pages 2312-2319

  Regenberg, Alan C ^a   Hutchinson, Lauren A ^b   Schanker, Benjamin ^c   Mathews, Debra J H ^a,d  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c BOSTON UNIVERSITY   (United States)

^d NONE   (United States)

Author keywords

Bioethics; Clinical trial; Stem cells; Therapy

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; HUMAN; INTERVENTION STUDY; MEDICAL RESEARCH; NONHUMAN; PHYSICIAN; QUALITY CONTROL; RISK ASSESSMENT; STEM CELL TRANSPLANTATION;

CLINICAL MEDICINE; CLINICAL TRIALS AS TOPIC; ETHICS, CLINICAL; HUMANS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 70349868339     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.132     Document Type: Article

References (53)

1. Arunanondchai J, Fink C. Trade in health services in the ASEAN region. Health Promotint 2006;21(suppl 1):59-66.
2. Horowitz MD, Rosensweig JA, Jones CA. Medical tourism: globalization of the healthcare marketplace. Medgenmed 2007;9:33
3. Enserink M. Biomedicine: selling the stem cell dream. Science 2006;313:160-163.
4. State of California. California Constitution, Article 35, Medical Research. Available at http://www.leginfo.ca.gov/.const/.article-35. Accessed October 30, 2008.
5. Aharonowiz M, Einstein O, Fainstein N et al. Neuroprotective effect of transplanted human embryonic stem cell-derived neural precursors in an animal model of multiple sclerosis. Plos One 2008;3:e3145.
6. Corti S, Nizzardo M, Nardini M et al. Neural stem cell transplantation can ameliorate the phenotype of a mouse model of spinal muscular atrophy. J Clin Invest 2008;118:3316-3330.
7. Arnesen H, Lunde K, Aakhus S et al. Cell therapy in myocardial infarction. Lancet 2007;369:2142-2143.
8. Boyle AJ, Schulman SP, Hare JM. Stem cell therapy for cardiac repair: ready for the next step. Circulation 2006;114:339-352. (Pubitemid 44297100)
9. Taupin P. HuCNS-SC (StemCells). Curr OpinMol Ther 2006;8:156-163.
10. Alper J. Geron gets green light for human trial of ES cell-derived product. Nature Biotechnology 2009;27:213-214.
11. Hinxton Group. World stem cell policies. Available at http://www.hinxtongroup.org/wp.html. Accessed October 30, 2008.
12. Food and Drug Administration. Current good tissue practice for human cell, tissue, and cellular and tissue-based product establishments; Inspection and Enforcement; Final Rule. Federal Register 69(226). Available at http://www.fda.gov/CbER/rules/gtp.pdf. Accessed October 30, 2008.
13. Moos M Jr. Stem-cell-derived products: an FDA update. Trends Pharmacol. Sci [Epub ahead of print].
14. Food and Drug Administration. FDA: Investigational new drug (IND) application process. Available at http://www.fda.gov/cder/regulatory/ applications/ind-page-1.htm. Accessed October 30, 2008.
15. Food and Drug Administration. Title 21 - Food and Drugs Chapter I - Food and Drug Administration, Department of Health and Human Services - Continued Part 312 - Investigational New Drug Application - Section 312.23 IND content and format. Code of Federal Regulations Title 21, Volume 5, Part 312. April 1, 2008. Available at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/ CFRSearch. cfm?CFRPart=312&showFR=1&subpartNode=21:5.0.1.1.3.2. Accessed October 30, 2008.
16. Regenberg A, Mathews DJ, Blass DM et al. The role of animal models in evaluating reasonable safety and efficacy for human trials of cell-based interventions for neurologic conditions. J Cereb. Blood Flow Metab [Epub ahead of print].
17. Medicines and Healthcare Products Regulatory Agency. Medicines and Healthcare Products Regulatory Agency: index. Available at http://www.mhra.gov. uk/index.htm. Accessed October 30, 2008.
18. European Medicines Agency. European Medicines Agency: home. Available at http://www.emea.europa.eu/home.htm. Accessed October 30, 2008.
19. Ministry of Health, Labour and Welfare. Welcome to the Ministry of Health, Labour and Welfare. Available at http://www.mhlw.go.jp/english/index. html. Accessed October 30, 2008.
20. State Food and Drug Administration, PR China. SFDA [English]. Available at http://eng.sfda.gov.cn/eng/. Accessed October 30, 2008.
21. Alpert JS. Are stem cells and genetic therapies ready for 'prime time'?Am J Med 2007;120:103-104.
22. Daley GQ, Scadden DT. Prospects for stem cell-based therapy. Cell 2008;132:544-548.
23. Daley GQ, Hyun I, Lindvall O. Mapping the road to the clinical translation of stem cells. Cell Stem Cell 2008;2:139-140.
24. Fox JL. FDA scrutinizes human stem cell therapies. Natbiotechnol 2008;26:598-599. (Pubitemid 351809572)
25. Kirouac DC, Zandstra PW. The systematic production of cells for cell therapies. Cell Stem Cell 2008;3:369-381.
26. Lau D, Ogbogu U, Taylor B et al. Stem cell clinics online: the direct-to-consumer portrayal of stem cell medicine. Cell Stem Cell 2008;3:591-594.
27. Dobkin BH, Curt A, Guest J. Cellular transplants in China: observational study from the largest human experiment in chronic spinal cord injury. Neurorehabilneural Repair 2006;20:5-13. (Pubitemid 43214453)
28. CareCure Community. Available at http://sci.rutgers.edu/index.php. Accessed October 30, 2008.
29. The Multiple Sclerosis Resource Centre. Available at http://www.msrc.co. uk. Accessed October 30, 2008.
30. ALS Therapy Development Institute Forum. Available at http://www.als.net/forum. Accessed October 30, 2008.
31. Yahoo Health Groups. Stem cell safety. Available at http://health. groups.yahoo.com/group/stemcellsafety/messages. Accessed October 30, 2008.
32. XE Universal Currency Converter. Available at http://www.xe.com/ucc/. Accessed October 30, 2008.
33. Ginis I, Rao MS. Toward cell replacement therapy: promises and caveats. Expneurol 2003;184:61-77. (Pubitemid 37444021)
34. Winkler T, von RP, Matziolis G, Mehta M, Perka C, Duda GN. Dose - response relationship of mesenchymal stem cell transplantation and functional regeneration after severe skeletal muscle injury in rats. Tissue Eng Part A [Epub ahead of print].
35. de Bruijn M, Mikkola H, Snoeck H, Keller G. Highlights from Philadelphia: ISSCR 2008. Cell Stem Cell 2008;3:259-264.
36. Baker M. Stem cell society condemns unproven treatments. Nature Reports: Stem Cells. June 26, 2008. Available at http://www.nature.com/stemcells/2008/ 0806/080626/full/stemcells.2008.98.html. Accessed October 30, 2008.
37. Aldhous P. New task force to tackle 'stem cell tourism.' New Scientist. com news service. June 13, 2008. Available at http://www.newscientist.com/ channel/health/dn14137-new-task-force-to-tackle-stemcelltourism. html. Accessed October 30, 2008.
38. Vanden Plas J. Thomson strikes note of caution at World Stem Cell Summit. Wisconsin Technology Network. September 22, 2008. Available at http://wistechnology.com/articles/5047/. Accessed October 30, 2008.
39. Johnston M. Stem cell scientists urge clinical trials in US JS Online. September 23, 2008. Available at http://www.jsonline.com/story/index.aspx?id= 798506. Accessed October 30, 2008.
40. Bargnes K. Scientists look ahead to stem cell research future. The Badger Herald. September 23, 2008. Available at http://badgerherald.com/news/2008/09/ 23/scientists-look-ahea.php. Accessed October 30, 2008.
41. Dawson L, Bateman-House AS, Mueller AD et al. Safety issues in cell-based intervention trials. Fertil Steril 2003;80:1077-1085. (Pubitemid 37377728)
42. Mathews DJ, Sugarman J, Bok H et al. Cell-based interventions for neurologic conditions: ethical challenges for early human trials. Neurology 2008;71:288-293.
43. Amariglio N, Hirshberg A, Scheithauer BW et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Medicine 2009;6:e1000029.
44. International Society for Stem Cell Research (2008). Patient handbook on stem cell therapies. Available at http://www.isscr.org/clinical-trans/pdfs/ ISSCRPatientHandbook.pdf. Accessed March 27, 2009.
45. International Campaign for Cures of spinal cord injury Paralysis (2007). Experimental treatments for spinal cord injury: what you should know if you are considering participation in a clinical trial. Available at http://www.icord. org/ICCP/Experimental-treatment-for-SCI-full.pdf. Accessed October 30, 2008.
46. Fowler G. Mystic healers & medicine shows blazing trails to wellness in the Old West and beyond. Santa Fe, NM Ancient City Press, 1997.
47. Kurian GT, Harahan JP. A historical guide to the US government, New York: Oxford University Press, 1998.
48. Mathews DJ, Donovan P, Harris J et al. Science and law. Integrity in international stem cell research collaborations. Science 2006;313:921-922.
49. Hinxton Group. Transnational Cooperation in Stem Cell Research. February 24, 2006. Available at http://www.hinxtongroup.org/au-trans-cs.html. Accessed October 30, 2008.
50. Hinxton Group. The Science, Ethics and Policy Challenges of Pluripotent Stem Cell-Derived Gametes. April 11, 2008. Available at http://www.hinxtongroup. org/au-pscdg-cs.html. Accessed October 30, 2008.
51. International Society for Stem Cell Research. Guidelines for the conduct of human embryonic stem cell research. December 21, 2006. Available at http://www.isscr.org/guidelines/ISSCRhESCguidelines2006.pdf. Accessed October 30, 2008.
52. International Stem Cell Forum. International Stem Cell Forum. Available at http://www.stemcellforum.org/index.cfm. Accessed October 30, 2008.
53. Hyun I, Lindvall O, Ahrlund-Richter L et al. New ISSCR guidelines underscore major principles for responsible translational stem cell research. Cell Stem Cell 2008;3:607-609.